Venture Life Group PLC Directorate Change (1262Y)
01 March 2017 - 6:01PM
UK Regulatory
TIDMVLG
RNS Number : 1262Y
Venture Life Group PLC
01 March 2017
Venture Life Group plc
("Venture Life" or the "Group")
Directorate Change
Venture Life (AIM: VLG), the international consumer self-care
group focused on developing, manufacturing and commercialising
products for the ageing population, announces the appointment of
Adrian Crockett as Chief Financial Officer, effective as of 6 March
2017.
Adrian joins Venture Life from Abbott Diabetes Care Ltd, a
division of Abbott Laboratories with an annual turnover of
approximately $1 billion, where he was Finance Director since
October 2011 and responsible for a team of 14 qualified finance
staff, reporting directly to the unit's Managing Director.
Before that, Adrian was a Financial Controller within PAREXEL, a
global Clinical Research Organisation with a turnover of $2
billion, and prior to that held a number of Finance and Planning
roles within organisations such as GlaxoSmithKline plc, Novartis
Vaccines & Diagnostics, Inc., and Anderson Consulting (now
Accenture).
Jerry Randall, CEO of Venture Life, commented: "I am delighted
to welcome Adrian to the Board as Chief Financial Officer. Adrian
has pursued an active career within the healthcare space, and has
enjoyed senior roles within some of the best known healthcare
companies in the world. With this extensive experience, in
particular in consumer healthcare and manufacturing operations, we
are confident Adrian will make a significant contribution to our
business as we continue to grow and deliver on our strategy of
becoming sustainably profitable."
Information to be disclosed under Schedule 2(g) and Rule 17 of
the AIM rules
Adrian Graham Crockett (aged 49)
Current Directorships Directorships in the last
five years
---------------------- -----------------------------
none Abbott Diabetes Care Limited
Other than the information contained in this announcement, there
is no further information required to be disclosed under Rule 17
and Schedule Two, paragraph (g) of the AIM Rules.
For further information please contact:
+44 (0) 1344 742
Venture Life Group PLC 870
Jerry Randall, Chief Executive
Officer
Panmure Gordon (UK) Limited (Nominated +44 (0) 20 7886
Adviser and Joint Broker) 2500
Freddy Crossley/Peter Steel/Duncan
Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Turner Pope Investments (TPI) Ltd +44 (0) 20 3621
(Joint Broker) 4120
James Pope/Ben Turner
Walbrook PR venturelife@walbrookpr.com
or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy +44 (0) 7980 541 893/ +44
(0) 7876 741 001
This announcement contains information which, prior to its
disclosure, was inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 (MAR).
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABRGDDIXDBGRI
(END) Dow Jones Newswires
March 01, 2017 02:01 ET (07:01 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024